Cambrex to Acquire Avista Pharma Solutions
Cambrex Corporation, a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, has entered into a definitive agreement to acquire Avista Pharma Solutions, a contract development, manufacturing, and testing organization, for approximately $252 million. With this acquisition, Cambrex will enter the large and growing market for early stage small molecule…
Cambrex Completes Purchase of Halo Pharma
Cambrex Corporation, a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), has completed the acquisition of Halo Pharma, a dosage form Contract Development and Manufacturing Organization (CDMO) located in Whippany, New Jersey and Mirabel, Québec, Canada, for approximately $425 million. This completes the transaction initially announced on July 23, 2018. The addition of…
Cambrex To Acquire CDMO Halo Pharma For $425M
Cambrex Corporation, a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), has entered into a definitive agreement to acquire Halo Pharma, a dosage form Contract Development and Manufacturing Organization (CDMO), majority owned by funds managed by the private investment firm SK Capital Partners, for approximately $425 million. With the acquisition of Halo, Cambrex…
Cambrex Invests $5M In Lab Expansion At Sweden Facility
Cambrex Corporation, a manufacturer of small molecule and generic Active Pharmaceutical Ingredients (APIs), is about to commence a $5 million expansion of laboratory facilities at its Karlskoga, Sweden, site, to augment capability and capacity for process development and scale up, handling of potent substances, crystallization studies, and solid phase characterization. Construction work on the three-story, 600-m2 (6,458-sq.-ft.) building will…
Cambrex Completes NC Expansion; Work Continues On IA HPAPI Plant
Cambrex Corporation, a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), has completed a pilot plant expansion at its High Point, NC, facility with the installation and commissioning of a fourth reactor suite, increasing the site’s reactor capacity by around 30 percent. The new 400-sq-ft suite includes two 2,000 liter glass lined reactors and…
Cambrex Expands Process R&D Capabilities Across North America
Cambrex Corporation, a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), announced Tuesday an investment to expand chemical and analytical development capabilities at its Charles City, IA plant. The project forms part of the company’s strategic plan to increase its development capacity and resources in North America. The expansion will see the construction…
Cambrex And AstraZeneca Mark Long-Term Supply Agreement
Cambrex and AstraZeneca hold ceremony to mark long-term supply agreement at Karlskoga, Sweden facility. Cambrex Corporation, a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), held an opening ceremony Tuesday with AstraZeneca at its Karlskoga, Sweden site to mark the commencement of a long-term manufacturing agreement between the two companies for a key intermediate.…
Cambrex Invests In New Small Scale Capacity In Iowa
Cambrex Adds Large Scale Manufacturing Capacity At Iowa Facility
Cambrex Corporation, a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), announced the completion of an expansion to its large scale production capacity at its Charles City, Iowa plant. The investment included the installation of 1,000 and 4,000 gallon glass lined reactors in addition to ancillary equipment. The new reactors have been installed…